Eva M Zwaan1, Alexander J J IJsselmuiden1, Joost van Rosmalen2, Robert-Jan M van Geuns3, Giovanni Amoroso4, Esther Moerman5, Marco J P F Ritt6, Ton A R Schreuders7, Marcel J M Kofflard1, Carlo A J Holtzer8. 1. Department of Cardiology, Albert Schweitzer Hospital, Dordrecht, The Netherlands. 2. Department of Biostatistics, Erasmus Medical Centre, Rotterdam, The Netherlands. 3. Department of Cardiology, Erasmus Medical Centre, Rotterdam, The Netherlands. 4. Department of Cardiology, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands. 5. Department of Plastic, Reconstructive, and Hand Surgery, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands. 6. Department of Plastic, Reconstructive, and Hand Surgery, VU University Medical Centre, Amsterdam, The Netherlands. 7. Hand & Pols center, Dordrecht, The Netherlands. 8. Department of Plastic, Reconstructive, and Hand Surgery, Albert Schweitzer Hospital, Dordrecht, The Netherlands.
Abstract
OBJECTIVE: The aim of this study is to provide a complete insight in the access-site morbidity and upper extremity function after Transradial Percutaneous Coronary Intervention (TR-PCI). BACKGROUND: In percutaneous coronary intervention the Transradial Approach (TRA) is gaining popularity as a default technique. It is a very promising technique with respect to post-procedure complications, but the exact effects of TRA on upper extremity function are unknown. METHODS AND RESULTS: The effects of trAnsRadial perCUtaneouS coronary intervention on upper extremity function (ARCUS) trial is a multicenter prospective cohort study that will be conducted in all patients admitted for TR-PCI. Clinical outcomes will be monitored during a follow-up of 6 months, with its primary endpoint at two weeks of follow-up. To investigate the complete upper extremity function, a combination of physical examinations and validated questionnaires will be used to provide information on anatomical integrity, strength, range of motion (ROM), coordination, sensibility, pain, and functioning in everyday life. Procedural and material specifications will be registered in order to include all possible aspects influencing upper extremity function. CONCLUSIONS: Results from this study will elucidate the effect of TR-PCI on upper extremity function. This creates the opportunity to further optimize TR-PCI, to make improvements in functional outcome and to prevent morbidity regarding full upper extremity function.
OBJECTIVE: The aim of this study is to provide a complete insight in the access-site morbidity and upper extremity function after Transradial Percutaneous Coronary Intervention (TR-PCI). BACKGROUND: In percutaneous coronary intervention the Transradial Approach (TRA) is gaining popularity as a default technique. It is a very promising technique with respect to post-procedure complications, but the exact effects of TRA on upper extremity function are unknown. METHODS AND RESULTS: The effects of trAnsRadial perCUtaneouS coronary intervention on upper extremity function (ARCUS) trial is a multicenter prospective cohort study that will be conducted in all patients admitted for TR-PCI. Clinical outcomes will be monitored during a follow-up of 6 months, with its primary endpoint at two weeks of follow-up. To investigate the complete upper extremity function, a combination of physical examinations and validated questionnaires will be used to provide information on anatomical integrity, strength, range of motion (ROM), coordination, sensibility, pain, and functioning in everyday life. Procedural and material specifications will be registered in order to include all possible aspects influencing upper extremity function. CONCLUSIONS: Results from this study will elucidate the effect of TR-PCI on upper extremity function. This creates the opportunity to further optimize TR-PCI, to make improvements in functional outcome and to prevent morbidity regarding full upper extremity function.
Authors: Eva Zwaan; Elena Cheung; Alexander IJsselmuiden; Carlo Holtzer; Ton Schreuders; Marcel Kofflard; Marco Alings; J Henk Coert Journal: Patient Relat Outcome Meas Date: 2022-06-27
Authors: Eva M Zwaan; Elena S Cheung; Alexander J J IJsselmuiden; Carlo A J Holtzer; Ton A R Schreuders; Marcel J M Kofflard; J Henk Coert Journal: J Interv Cardiol Date: 2022-09-06 Impact factor: 1.776